Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)

Trial Profile

Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Von Willebrand disease
  • Focus Adverse reactions
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 12 Sep 2018 According to the Shire media release, based on the data from this and other two phase 3 trials (700243677 and 700251088), the European Commission (EC) has granted Marketing Authorization for VEYVONDI [vonicog alfa, recombinant von Willebrand factor (rVWF)] for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (with von Willebrand disease (VWD) when desmopressin (DDAVP) treatment alone is ineffective or not indicated
    • 02 Jul 2018 According to the Shire media release, committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the granting of marketing authorization in the European Union for VEYVONDI, for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease, based on the data from this and other two trials (700243677 and 700251088).
    • 12 Dec 2017 Results of post-hoc analysis of this and other two studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top